Comparison between the Effectiveness of Oral Phloroglucin and Cimetropium Bromide as Premedication for Diagnostic Esophagogastroduodenoscopy: An Open-Label, Randomized, Comparative Study.
- Author:
Hye Won YUN
1
;
Ki Nam SHIM
;
Sun Kyung NA
;
Jae In RYU
;
Min Jin LEE
;
Eun Mi SONG
;
Seong Eun KIM
;
Hye Kyoung JUNG
;
Sung Ae JUNG
Author Information
- Publication Type:Comparative Study ; Randomized Controlled Trial ; Original Article
- Keywords: Upper endoscopy; Phloroglucin; Cimetropium
- MeSH: Atropine; Endoscopy; Endoscopy, Digestive System*; Glucagon; Humans; Incidence; Mouth; Parasympatholytics; Patient Compliance; Peristalsis; Premedication*; Prospective Studies; Scopolamine Hydrobromide
- From:Clinical Endoscopy 2015;48(1):48-51
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: Suppression of gastrointestinal (GI) peristalsis during GI endoscopy commonly requires antispasmodic agents such as hyoscine butylbromide, atropine, glucagon, and cimetropium bromide. This study examined the efficacy of oral phloroglucin for the suppression of peristalsis, its impact on patient compliance, and any associated complications, and compared it with intravenous or intramuscular cimetropium bromide administration. METHODS: This was a randomized, investigator-blind, prospective comparative study. A total of 172 patients were randomized into two groups according to the following medications administered prior to upper endoscopy: oral phloroglucin (group A, n=86), and cimetropium bromide (group B, n=86). The numbers and the degrees of peristalsis events at the antrum and second duodenal portion were assessed for 30 seconds. RESULTS: A significantly higher number of gastric peristalsis events was observed in group A (0.49 vs. 0.08, p<0.001), but the difference was not clinically significant. No significant difference between both groups was found in the occurrence of duodenal peristalsis events (1.79 vs. 1.63, p=0.569). The incidence of dry mouth was significantly higher with cimetropium bromide than with phloroglucin (50% vs. 15.1%, p<0.001). CONCLUSIONS: Oral phloroglucin can be used as an antispasmodic agent during upper endoscopy, and shows antispasmodic efficacy and adverse effects similar to those of cimetropium bromide.
